中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2013年
7期
575-578
,共4页
蔡婧%周婷婷%郭常辉%杜姝姗
蔡婧%週婷婷%郭常輝%杜姝姍
채청%주정정%곽상휘%두주산
重组人甲状旁腺素(1-34)%骨硬化蛋白%骨质疏松%绝经后
重組人甲狀徬腺素(1-34)%骨硬化蛋白%骨質疏鬆%絕經後
중조인갑상방선소(1-34)%골경화단백%골질소송%절경후
Recombinant human parathyroid hormone (1-34)%Sclerostin%Osteoporosis%Postmenopausal
目的 了解绝经后妇女血清骨硬化蛋白(sclerostin,SO)水平差异以及予以PTH治疗前后SO水平的变化,进一步探讨SO与雌二醇、骨密度等指标的相关性.方法 选择绝经后妇女95例,根据骨密度测量结果分为正常对照组(41例)和骨质疏松组(54例),测量受试者体重指数、血清碱性磷酸酶(ALP)、雌二醇、血钙、磷、SO等.骨质疏松组予以重组人甲状旁腺素(1-34)[rhPTH(1-34)] 20μg/d皮下注射,同时口服钙片500 mg/d,分别于治疗6个月、12个月时检测受试者血钙、磷、骨密度、血清ALP、雌二醇及SO等指标,并进行统计学分析.结果 (1)治疗前骨质疏松组血清SO含量显著高于正常对照组(P＜0.05),SO与雌二醇、骨密度呈负相关,与年龄、绝经年限呈正相关(P＜0.05)；(2)经rhPTH (1-34)治疗6个月和治疗12个月时骨质疏松组血清SO水平较治疗前逐渐下降(P＜0.01).结论 绝经后骨质疏松患者血清SO较正常对照组增高,与雌二醇、骨密度密切相关,经rhPTH (1-34)治疗后血清SO水平逐渐下降,提示SO可能参与了绝经后骨质疏松的发生发展.
目的 瞭解絕經後婦女血清骨硬化蛋白(sclerostin,SO)水平差異以及予以PTH治療前後SO水平的變化,進一步探討SO與雌二醇、骨密度等指標的相關性.方法 選擇絕經後婦女95例,根據骨密度測量結果分為正常對照組(41例)和骨質疏鬆組(54例),測量受試者體重指數、血清堿性燐痠酶(ALP)、雌二醇、血鈣、燐、SO等.骨質疏鬆組予以重組人甲狀徬腺素(1-34)[rhPTH(1-34)] 20μg/d皮下註射,同時口服鈣片500 mg/d,分彆于治療6箇月、12箇月時檢測受試者血鈣、燐、骨密度、血清ALP、雌二醇及SO等指標,併進行統計學分析.結果 (1)治療前骨質疏鬆組血清SO含量顯著高于正常對照組(P＜0.05),SO與雌二醇、骨密度呈負相關,與年齡、絕經年限呈正相關(P＜0.05)；(2)經rhPTH (1-34)治療6箇月和治療12箇月時骨質疏鬆組血清SO水平較治療前逐漸下降(P＜0.01).結論 絕經後骨質疏鬆患者血清SO較正常對照組增高,與雌二醇、骨密度密切相關,經rhPTH (1-34)治療後血清SO水平逐漸下降,提示SO可能參與瞭絕經後骨質疏鬆的髮生髮展.
목적 료해절경후부녀혈청골경화단백(sclerostin,SO)수평차이이급여이PTH치료전후SO수평적변화,진일보탐토SO여자이순、골밀도등지표적상관성.방법 선택절경후부녀95례,근거골밀도측량결과분위정상대조조(41례)화골질소송조(54례),측량수시자체중지수、혈청감성린산매(ALP)、자이순、혈개、린、SO등.골질소송조여이중조인갑상방선소(1-34)[rhPTH(1-34)] 20μg/d피하주사,동시구복개편500 mg/d,분별우치료6개월、12개월시검측수시자혈개、린、골밀도、혈청ALP、자이순급SO등지표,병진행통계학분석.결과 (1)치료전골질소송조혈청SO함량현저고우정상대조조(P＜0.05),SO여자이순、골밀도정부상관,여년령、절경년한정정상관(P＜0.05)；(2)경rhPTH (1-34)치료6개월화치료12개월시골질소송조혈청SO수평교치료전축점하강(P＜0.01).결론 절경후골질소송환자혈청SO교정상대조조증고,여자이순、골밀도밀절상관,경rhPTH (1-34)치료후혈청SO수평축점하강,제시SO가능삼여료절경후골질소송적발생발전.
Objective To investigate changes in serum sclerostin (SO) in postmenopausal women before and after treatment with recombinant human parathyroid hormone (1-34) [rhPTH (1-34)],and to explore the relationship of serum SO with estradiol (E2),and bone mineral density (BMD).Methods Ninety-five postmenopausal women were divided into normal BMD group (n =41) and osteoporosis group (n =54).Body mass index,alkaline phosphatase (ALP),serum E2,calcium,phosphate,and SO were determined in both groups.The patients in osteoporosis group were treated with rhPTH (1-34) 20 μg/d by subcutaneous injection and oral calcium 500 mg/d for 12 months.Serum calcium,serum phosphate,BMD,serum ALP,serum E2,and sclerostin were determined in osteoporosis group by 6 months and 12 months of treatment.Results (1) Serum level of SO in osteoporosis group was raised significantly as compared with normal BMD group (P ＜ 0.05) ; E2 and BMD were negatively correlated with SO; age and postmenopausal years were positively correlated with SO (P ＜ 0.05).(2) Serum SO was reduced gradually with treatment of rhPTH (1-34) by 6 months and 12 months (P ＜ 0.05).Conclusions Serum SO was increased in postmenopausal women,which was related to E2 and BMD,and was reduced gradually with treatment of rhPTH (1-34).SO may participate in the development of postmenopausal osteoporosis.
